GENFIT Secures $200M to Revolutionize Treatments for Rare Liver Diseases

GENFIT is excited to announce that it has successfully raised €200,000,000 in its latest funding round, marking a significant milestone in the company’s journey towards transforming the therapeutic landscape for patients with rare and severe liver diseases. This substantial capital injection reinforces GENFIT’s long-standing commitment to addressing high unmet medical needs and will be strategically allocated to advance its diversified research and development pipeline. With a rich history of pioneering liver disease research spanning more than two decades, GENFIT has consistently demonstrated its ability to develop high-potential assets from early-stage discovery to late development and pre-commercialization phases. The recent funding will further support the continued evaluation of promising therapies, including the regime studied in the successful 52-week readout of the Phase 3 ELATIVE® trial for Primary Biliary Cholangitis, and will boost several other clinical and pre-clinical programs. Notably, funds will be directed towards advancing five clinical and pre-clinical projects in the acute on chronic liver failure space and enhancing research efforts in hepatic encephalopathy, cholangiocarcinoma, urea cycle disorders, and organic acidemias. Additionally, investment in the diagnostic franchise that targets Metabolic dysfunction-associated steatohepatitis (MASH) and ammonia monitoring will further consolidate GENFIT’s leadership in the field. With facilities in France, Switzerland, and the United States, and with the support of key shareholders such as IPSEN, GENFIT is poised to accelerate innovation and deliver transformative therapeutic options to patients most in need. This funding milestone underlines GENFIT’s unwavering mission to improve lives and shape the future of treatment for complex liver disorders.